Table 3.
Univariate hazard ratios for treatment and staging for OS and DSS based on the seventh and eighth edition AJCC for the HPV-selected cohort.
| Exposed | OS HR (95% CI) in survival months | OS HR P-value | DSS HR (95% CI) in survival months | DSS HR P-value | |
|---|---|---|---|---|---|
| Radiation | 8597/9554 | 0.28 (0.25-0.30) | <.001 | 0.25 (0.22-0.27) | <.001 |
| Chemotherapy | 8148/9554 | 0.51 (0.47-0.56) | <.001 | 0.49 (0.44-0.53) | <.001 |
| Seventh edition staging | |||||
| Stage I | 188/9554 | -------------------- | --------- | ---------------------- | ----------- |
| Stage II | 560/9554 | 0.78 (0.59-1.03) | .079 | 0.75 (0.55-1.04) | .086 |
| Stage III | 1784/9554 | 0.77 (0.60-0.99) | .039 | 0.74 (0.55-0.98) | .038 |
| Stage IVA | 6048/9554 | 0.91 (0.72-1.15) | .426 | 0.93 (0.71-1.23) | .612 |
| Stage IVB | 580/9554 | 1.56 (1.21-2.02) | <.001 | 1.78 (1.32-2.40) | <.001 |
| Stage IVC | 392/9554 | 4.44 (3.44-5.74) | <.001 | 5.23 (3.90-7.01) | <.001 |
| Eighth edition staging | |||||
| Stage I | 1836/9554 | ||||
| Stage II | 5326/9554 | 1.01 (0.91-1.11) | .881 | 1.07 (0.95-1.20) | .256 |
| Stage III | 1998/9554 | 2.33 (2.10-2.59) | <.001 | 2.64 (2.34-2.98) | <.001 |
| Stage IV | 392/9554 | 6.14 (5.33-7.06) | <.001 | 7.62 (6.53-8.90) | <.001 |
Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; DSS, disease-specific survival; HPV, human papilloma virus; HR, hazard ratio; OS, overall survival.